
ENTX Stock Forecast & Price Target
ENTX Analyst Ratings
Bulls say
Entera Bio is a clinical-stage biopharmaceutical company with a strong product pipeline addressing unmet needs in various chronic medical conditions. The recent equity financing of $10 million and the potential for an additional $14.5 million from warrant exercise provides the company with a solid runway for its pivotal program initiation. With a valuation of $750 million and a price objective of $9 per share, there is significant upside potential for investors. However, risks to achieving this price target include clinical development delays, negative results from pivotal studies, and slow uptake in the market for its products. The recent key opinion leader webinar highlighted the vast market for Entera Bio's products and the potential for high adoption rates among prescribing physicians. This further strengthens the positive outlook for the company and its potential for success in the future.
Bears say
Entera Bio is a biopharmaceutical company with a negative outlook, due to concerns about the potential commercial performance of its product candidates. While their treatments for osteoporosis, hypoparathyroidism, obesity, and short bowel syndrome may have positive clinical results, the need for daily or weekly injections may deter patients and limit the market potential. Additionally, the company's plans to enter clinical trials for its next-generation formulation may delay the potential launch of its product until 2029, further hindering its commercial success.
This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ENTX Analyst Forecast & Price Prediction
Start investing in ENTX
Order type
Buy in
Order amount
Est. shares
0 shares